Wegovy is a FDA-approved injectable medication designed to aid weight loss in adults with obesity or overweight conditions.
It mimics a hormone called GLP-1 (glucagon-like peptide-1) to regulate appetite, reduce food intake, and promote satiety.
Clinical trials demonstrate its effectiveness in achieving substantial weight loss when combined with lifestyle modifications.
It supports sustainable weight loss, improves metabolic health, and reduces the risk of obesity-related complications.
Healthcare providers administer Wegovy weekly via injection, following specific dosage guidelines.
While generally well-tolerated, potential side effects and contraindications require professional guidance.
It complements diet, exercise, and behavioral changes to optimize weight loss outcomes.
Positive feedback includes improved weight control and enhanced quality of life among users.